COURSE DESCRIPTION:  

A multidisciplinary team approach to care is fostered through peer-to-peer discussion and collaboration. The team discussion pertaining to diagnosis and treatment includes radiological and pathological findings and immunohistochemical testing to bridge gaps across the continuum of care and enhance the overall quality of patient-centered breast cancer care.

TARGET AUDIENCE:

Medical Oncologists, Radiation Oncologists, Breast Cancer Surgeons, General Surgeons, Pathologists, Radiologists, Gynecologists, Pharmacists, Nurses, Social Workers, Radiologic Technologists, Patient Care Facilitators and all personnel involved in the care of the breast cancer patient.

LEARNING OBJECTIVES:

•    Improve clinical decision making, clinical outcomes, and patient experience via a multidisciplinary team approach. Group discussion include prospective patient care management, national treatment guidelines, staging, and options and eligibility for genetic testing, clinical research studies, and supportive care services.

•    Develop a comprehensive treatment plan for breast oncology patients leveraging imaging and pathology testing results and meet Commission on Cancer accreditation standards compliance. 
 

FACULTY :

Jane E. Mendez, M.D. 
Chief, Breast Surgery  
Miami Cancer Institute 

Dora Escobeda, APRN
Miami Cancer Institute

Stephanie Moreno, PA-C
Miami Cancer Institute
 

Jane Mendez, M.D., conference director of this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

Dora Escobeda and Stephanie Moreno, interprofessional coordinators of this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentations or discussions will not include off-label or unapproved product usage.

DMT coordinators and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.
 

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.